Fennec Pharmaceuticals Inc.
NASDAQ:FENC
5.64 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Fennec Pharmaceuticals Inc. |
Symbool | FENC |
Munteenheid | USD |
Prijs | 5.64 |
Beurswaarde | 154,692,228 |
Dividendpercentage | 0% |
52-weken bereik | 3.96 - 11.49 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Rostislav Raykov |
Website | https://www.fennecpharma.com |
An error occurred while fetching data.
Over Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)